Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Dupilumab significantly reduces severe exacerbations and improves lung function in children with moderate-to-severe type 2 ...

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The Bergendorff scholarship was founded in 2022 in honor of Anders Bergendorff, the former program director of the master ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

Efficacy of Medication in Young Children with Atopic Dermatitis: Study FindsResearch at National Jewish Health and other ...

Upstream Bio's verekitug targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026 ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...

Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.